MedCity News

AstraZeneca Places a $2B Bet on a Summit Therapeutics Cancer Drug

MedCity Pivot Podcast: A Conversation With AliveCor’s Priya Abani

In this episode of the MedCity Pivot Podcast, CEO Priya Abani talks about the evolution of AliveCor, one of the earliest digital health companies.

By Arundhati Parmar

Opinion

The Illegal Drug Marketplace in Your Patients’ Pockets

Patients obtaining drugs through social media, medical spas, or telehealth platforms are not the same as patients obtaining drugs through more traditional illicit channels because they often believe what they are receiving is a clinically validated product. This means they may present with unexplained symptoms without realizing their online purchase is even relevant to the conversation

By Fred Mills

DreaMed Wins FDA Clearance for CGM-Driven Insulin Automation Tool for Both Type 2 Injection Regimens

DreaMed Diabetes has received FDA 510(K) clearance for MODI, a mobile app that uses CGM (continuous glucose monitoring) data to provide insulin dosing recommendations for people with Type 2 diabetes who need both basal insulin and fast-acting injections.

By Jenna Congdon

Latest Video

Latest News

Consumer / Employer

New Coalition Launches to Expand Direct Contracting

The Association for Direct Care launched a coalition focused on expanding direct contracting to lower healthcare costs.

By Marissa Plescia

BioPharma, Pharma

Merck Pays $400M for Cancer Drug Prospect From China-Based SciBrunch

Merck now has global rights to a SciBrunch Therapeutics drug candidate designed to block mutated versions of the cancer-driving protein KRAS G12D. This class of targeted cancer therapies includes clinical-stage assets from Revolution Medicines, BridgeBio Oncology Therapeutics, and Verastem Oncology.

By Frank Vinluan

Where Will AI Deployment Benefit Payers the Most?

We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey.

By MedCity News

MedCity Influencers

Beyond One-Size-Fits-All: Women, Substance Use, and the Need for Gender-Responsive Care

While SUD affects people across all demographics, a growing body of research and clinical experience makes one point clear: gender meaningfully influences how substance use develops, how it is experienced, and what supports effective treatment.

By Wendy Insalaco and Jami Barney

BioPharma, Pharma

Mirum Pharma Pill Lands FDA Approval for Ultra-Rare Bone Growth Disorder

Mirum Pharmaceuticals’ Atebrioz is the third FDA-approved drug for fibrodysplasia ossificans progressiva (FOP), but it brings advantages over the two other products for this rare disease that leads to bone growth in soft tissue. Mirum acquired Atebrioz from Incyte earlier this year.

By Frank Vinluan

Legal, Artificial Intelligence

When AI Gets Medicine Wrong, Who’s Liable?

As AI technology in healthcare becomes more deeply involved in the complex, high-stakes tasks of diagnosis and treatment planning, traditional lines of accountability will become less clear. Where does the buck stop for AI-supported medical care?

By Jenna Congdon

Opinion

Fifty Years of Pediatric Rheumatology, but Children Still Can’t Access the Treatments They Need

As a country, we have developed treatments capable of improving the quality of life and preventing long-term damage for children with rheumatic conditions, yet many children cannot obtain them when they need them most. This needs to change.

By Miriah Gillespie-Taylor

MedCity Influencers

MedTech Commercialization Gap: Moving Beyond Technical Viability

What are the common reasons that a prototype fails to make the transition? There are several, but they all boil down to early-stage programs ignoring the business problem in favor of the technology problem.

By Adam Hesse

Physicians

Report: High Drug Costs Are Creating Hidden Burden for Physicians

When drug prices are too high for patients, physicians take on additional workload to find solutions. A newly released 2026 Physician Drug Cost Survey by RazorMetrics examined how prescription cost pressures affect physicians’ practices.

By Jenna Congdon

BioPharma, Pharma

Gene Silencing-Biotech ADARx Makes Some Noise With $535M Stock Market Debut

ADARx Pharmaceuticals upsized its IPO and raised additional cash through a private placement with partner AbbVie. Lead ADARx program onvuzosiran is in Phase 3 testing for the rare disease hereditary angioedema, and the RNA therapies pipeline also spans immunological disorders, cardiovascular diseases and obesity, and neurodegeneration.

By Frank Vinluan

MedCity Influencers

AI Goes All In To Support Nursing Teams: Ambient Charting is Just the Start

The question is whether these AI tools will be another fragmented layer of technology or true assistants to help them spend more time on patient care.

By Sarah Visker

Health Tech

UHC, Cigna and Centene Sign On to New National Shared Credentialing Program

CertifyOS launched a shared credentialing program that allows providers to submit their information once for multiple health plans.

By Marissa Plescia

BioPharma, Pharma

Lilly Again Looks to China for New Drugs, Paying InnoCare $100M to Start R&D Pact

Eli Lilly’s partnership with InnoCare Pharma follows deals struck this year with other China-based companies. While indications for the new alliance remain undisclosed, InnoCare specializes in oncology and autoimmune drugs.

By Frank Vinluan

MedCity Influencers, Opinion

From OpenNotes to “Doc Can I Record You?” Why Physicians Should Embrace Era of Accountability

Healthcare has a habit of embracing patient empowerment right up until patients become powerful.

By Sachin H. Jain

MedCity Influencers

Modernizing Medicare Advantage for the Next Generation of Seniors

The Centers for Medicare & Medicaid Services (CMS) took constructive steps in its 2027 final rule and rate announcement, particularly on payment integrity and quality measurement. But those steps are not the finish line. Policymakers should further modernize MA to strengthen competition, transparency and accountability. Here’s where to start.

By John Kao